RNS Number : 7388T
GlaxoSmithKline PLC
16 October 2017
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.275

75.595 (personal contribution)

£15.275

187.204 (personal contribution)

£15.275

203.821 (personal contribution)

£15.275

75.595 (personal contribution)

£15.275

187.191 (personal contribution)

£15.275

203.809 (personal contribution)

£15.275

75.595 (matching shares)

£15.275

187.204 (matching shares)

£15.275

203.821 (matching shares)

£15.275

75.595 (matching shares)

£15.275

187.191 (matching shares)

£15.275

203.809 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,866.43

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.275

55.361 (personal contribution)

£15.275

127.190 (personal contribution)

£15.275

106.128 (personal contribution)

£15.275

55.361 (personal contribution)

£15.275

106.115 (personal contribution)

£15.275

55.361 (matching shares)

£15.275

127.19 (matching shares)

£15.275

106.128 (matching shares)

£15.275

55.361 (matching shares)

£15.275

106.115 (matching contribution)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

900.310

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Debruyne

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.275

178.377 (personal contribution)

£15.275

178.365 (personal contribution)

£15.275

178.377 (matching shares)

£15.275

178.365 (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

713.484

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.275

105.590 (personal contribution)

£15.275

247.218 (personal contribution)

£15.275

185.166 (personal contribution)

£15.275

105.576 (personal contribution)

£15.275

247.205 (personal contribution)

£15.275

185.166 (personal contribution)

£15.275

105.590 (matching shares)

£15.275

247.218 (matching shares)

£15.275

185.166 (matching shares)

£15.275

105.576 (matching shares)

£15.275

247.205 (matching shares)

£15.275

185.166 (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

2,151.842

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.275

38.762 (personal contribution)

£15.275

91.407 (personal contribution)

£15.275

67.081 (personal contribution)

£15.275

38.762 (personal contribution)

£15.275

91.407 (personal contribution)

£15.275

67.068 (personal contribution)

£15.275

38.762 (matching shares)

£15.275

91.407 (matching shares)

£15.275

67.081 (matching shares)

£15.275

38.762 (matching shares)

£15.275

91.407 (matching shares)

£15.275

67.068 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

788.974

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$41.020

75.963 (personal contribution)

$41.020

75.963 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

151.926

$41.020

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.275

62.115 (personal contribution)

£15.275

116.331 (personal contribution)

£15.275

84.422 (personal contribution)

£15.275

62.115 (personal contribution)

£15.275

116.331 (personal contribution)

£15.275

84.409 (personal contribution)

£15.275

62.115 (matching shares)

£15.275

116.331 (matching shares)

£15.275

84.422 (matching shares)

£15.275

62.115 (matching shares)

£15.275

116.331 (matching shares)

£15.275

84.409 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,051.446

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.275

83.607 (personal contribution)

£15.275

170.189 (personal contribution)

£15.275

127.067 (personal contribution)

£15.275

83.594 (personal contribution)

£15.275

170.189 (personal contribution)

£15.275

127.067 (personal contribution)

£15.275

83.607 (matching shares)

£15.275

170.189 (matching shares)

£15.275

127.067 (matching shares)

£15.275

83.594 (matching shares)

£15.275

170.189 (matching shares)

£15.275

127.067 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,523.426

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.275

56.787 (personal contribution)

£15.275

104.127 (personal contribution)

£15.275

79.994 (personal contribution)

£15.275

56.787 (matching shares)

£15.275

104.127 (matching shares)

£15.275

79.994 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

481.816

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D E Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$41.020

43.227 (personal contribution)

$41.020

97.329 (personal contribution)

$41.020

80.611 (personal contribution)

$41.020

43.227 (personal contribution)

$41.020

97.329 (personal contribution)

$41.020

80.599 (personal contribution)

$41.020

43.227 (matching shares)

$41.020

97.329 (matching shares)

$41.020

80.611 (matching shares)

$41.020

43.227 (matching shares)

$41.020

97.329 (matching shares)

$41.020

80.599 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

884.644

$41.020

 

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.275

123.070 (personal contribution)

£15.275

200.197 (personal contribution)

£15.275

138.016 (personal contribution)

£15.275

123.070 (personal contribution)

£15.275

200.197 (personal contribution)

£15.275

138.016 (personal contribution)

£15.275

123.070 (matching shares)

£15.275

200.197 (matching shares)

£15.275

138.016 (matching shares)

£15.275

123.070 (matching shares)

£15.275

200.197 (matching shares)

£15.275

138.016 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,845.132

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEQLFFDBFEFBF